RATIONALE AND OBJECTIVE: Neuropsychiatric systemic lupus erythematosus (NPSLE) is a diagnostically challenging, severe, and life-threatening condition, which is currently lacking a "gold standard." Our aim with this study is to look for magnetic resonance (MR) perfusion differences in NPSLE, SLE, and healthy control (HC) patients and correlate our findings with clinical parameters. MATERIALS AND METHODS: Twenty-four NPSLE patients, 21 SLE patients, and 21 HC underwent dynamic susceptibility contrast enhanced MR perfusion using a 3-T scanner. Nine prospectively selected intracranial regions of interest were placed in white and gray matter and the cerebral blood flow (CBF), cerebral blood volume (CBV), and mean transit time (MTT) values were calculated. Subjects underwent clinical evaluation with SLEDAI and serum antibodies. RESULTS: The SLE patients had higher CBF and CBV compared to the HC overall (P = .01) and in specific areas (P = .03-.048). SLE patients with signs of active disease (elevated SLEDAI and anti-double-stranded DNA) had significantly elevated CBV, CBF, and MTT in the posterior cingulate gyrus (P = .01-.02). No significant difference was seen in the magnetic resonance perfusion measurements of NPSLE patients compared to SLE and HC, although the NPSLE patients also showed higher CBV variability compared to the SLE (P = .0004) and HC cohort (P < .0001). CONCLUSION: SLE patients have increased CBV and CBF compared to healthy controls. The SLE patients with clinical markers for active disease have elevated CBV, CBF, and MTT in the posterior cingulate gyrus. NPSLE patients show increased variability in perfusion measurements, which may explain why susceptibility contrast enhanced MRI has not yet provided a specific target for NPSLE.
RATIONALE AND OBJECTIVE:Neuropsychiatric systemic lupus erythematosus (NPSLE) is a diagnostically challenging, severe, and life-threatening condition, which is currently lacking a "gold standard." Our aim with this study is to look for magnetic resonance (MR) perfusion differences in NPSLE, SLE, and healthy control (HC) patients and correlate our findings with clinical parameters. MATERIALS AND METHODS: Twenty-four NPSLE patients, 21 SLEpatients, and 21 HC underwent dynamic susceptibility contrast enhanced MR perfusion using a 3-T scanner. Nine prospectively selected intracranial regions of interest were placed in white and gray matter and the cerebral blood flow (CBF), cerebral blood volume (CBV), and mean transit time (MTT) values were calculated. Subjects underwent clinical evaluation with SLEDAI and serum antibodies. RESULTS: The SLEpatients had higher CBF and CBV compared to the HC overall (P = .01) and in specific areas (P = .03-.048). SLEpatients with signs of active disease (elevated SLEDAI and anti-double-stranded DNA) had significantly elevated CBV, CBF, and MTT in the posterior cingulate gyrus (P = .01-.02). No significant difference was seen in the magnetic resonance perfusion measurements of NPSLE patients compared to SLE and HC, although the NPSLE patients also showed higher CBV variability compared to the SLE (P = .0004) and HC cohort (P < .0001). CONCLUSION:SLEpatients have increased CBV and CBF compared to healthy controls. The SLEpatients with clinical markers for active disease have elevated CBV, CBF, and MTT in the posterior cingulate gyrus. NPSLE patients show increased variability in perfusion measurements, which may explain why susceptibility contrast enhanced MRI has not yet provided a specific target for NPSLE.
Authors: Jessy J Mouannes-Srour; Wanyong Shin; Sameer A Ansari; Michael C Hurley; Parmede Vakil; Bernard R Bendok; John L Lee; Colin P Derdeyn; Timothy J Carroll Journal: Magn Reson Med Date: 2011-12-12 Impact factor: 4.668
Authors: L Emmi; M Bramati; M T De Cristofaro; M Mascalchi; G Dal Pozzo; G P Marconi; G Massai; A Passaleva Journal: Clin Exp Rheumatol Date: 1993 Jan-Feb Impact factor: 4.473
Authors: K Waterloo; R Omdal; H Sjöholm; W Koldingsnes; E A Jacobsen; J A Sundsfjord; G Husby; S I Mellgren Journal: J Neurol Date: 2001-07 Impact factor: 4.849
Authors: Patricia Cagnoli; Richard E Harris; Dan Frechtling; George Berkis; Richard H Gracley; Courtney C Graft; Suzan E Lowe; Thomas L Chenevert; William J McCune; Stephen Gebarski; Pia C Sundgren Journal: Acad Radiol Date: 2013-10 Impact factor: 3.173
Authors: J M Chi; M Mackay; A Hoang; K Cheng; C Aranow; J Ivanidze; B Volpe; B Diamond; P C Sanelli Journal: AJNR Am J Neuroradiol Date: 2019-02-21 Impact factor: 3.825
Authors: Pamela Munguía-Realpozo; Mario García-Carrasco; Claudia Mendoza-Pinto; María de Lourdes Galaviz-Silva; Ivet Etchegaray-Morales; Socorro Méndez-Martínez; Álvaro José Montiel-Jarquín; Luis G Vázquez de Lara; Luis H Silveira Journal: Clin Rheumatol Date: 2022-05-27 Impact factor: 3.650
Authors: Sanne van Erp; Ece Ercan; Perla Breedveld; Lianne Brakenhoff; Eidrees Ghariq; Sophie Schmid; Matthias van Osch; Mark van Buchem; Bart Emmer; Jeroen van der Grond; Ron Wolterbeek; Daniel Hommes; Herma Fidder; Nic van der Wee; Tom Huizinga; Désirée van der Heijde; Huub Middelkoop; Itamar Ronen; Andrea van der Meulen-de Jong Journal: World J Gastroenterol Date: 2017-02-14 Impact factor: 5.742
Authors: Tobias Schmidt-Wilcke; Patricia Cagnoli; Page Wang; Thomas Schultz; Anne Lotz; William J Mccune; Pia C Sundgren Journal: Neuroimage Clin Date: 2014-07-10 Impact factor: 4.881